Literature DB >> 19165486

[Flat epithelial atypia].

W Böcker1, D Hungermann, J Tio, S Weigel, T Decker.   

Abstract

According to the WHO, flat epithelial atypia (FEA) is defined as a neoplastic epithelial proliferation of ductal type in either a single or in multiple terminal duct lobular unit(s) limited to the periphery of the ductules in a clinging growth pattern. The atypical cells may form between one and several layers of epithelial cells that show low grade cytologic atypia. FEA most often presents as mammographic microcalcifications, which are typically round (secretory type and psammomatous calcification in an eosinophilic matrix, so-called ossifying calcifications). Clinical relevance is dependent on whether the lesion appears in isolation or whether it is an excision biopsy or a minimally invasive biopsy. Currently available data suggest that the risk of subsequent breast carcinoma in the ipsilateral breast is very low following the diagnosis of FEA. The differential diagnosis should include atypical ductal hyperplasia, low-grade clinging ductal carcinoma in situ, blunt duct adenosis and apocrine metaplasia.

Entities:  

Mesh:

Year:  2009        PMID: 19165486     DOI: 10.1007/s00292-008-1123-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

1.  Columnar cell hyperplasia is associated with lobular carcinoma in situ and tubular carcinoma.

Authors:  P P Rosen
Journal:  Am J Surg Pathol       Date:  1999-12       Impact factor: 6.394

2.  Persistent and atypical lobules in the human breast may be precancerous.

Authors:  S R Wellings; H M Jensen; M R DeVault
Journal:  Experientia       Date:  1976-11-15

3.  An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions.

Authors:  S R Wellings; H M Jensen; R G Marcum
Journal:  J Natl Cancer Inst       Date:  1975-08       Impact factor: 13.506

4.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Long-term follow-up of in situ carcinoma of the breast.

Authors:  V Eusebi; E Feudale; M P Foschini; A Micheli; A Conti; C Riva; S Di Palma; F Rilke
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

6.  Atypical cystic lobule of the breast: an early stage of low-grade ductal carcinoma in-situ.

Authors:  T Oyama; K Iijima; H Takei; J Horiguchi; Y Iino; T Nakajima; F Koerner
Journal:  Breast Cancer       Date:  2000       Impact factor: 4.239

7.  Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis.

Authors:  F Moinfar; Y G Man; L Arnould; G L Bratthauer; M Ratschek; F A Tavassoli
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

8.  Cancerization of small ectatic ducts of the breast by ductal carcinoma in situ cells with apocrine snouts: a lesion associated with tubular carcinoma.

Authors:  N S Goldstein; B A O'Malley
Journal:  Am J Clin Pathol       Date:  1997-05       Impact factor: 2.493

9.  Columnar alteration with prominent apical snouts and secretions: a spectrum of changes frequently present in breast biopsies performed for microcalcifications.

Authors:  J L Fraser; S Raza; K Chorny; J L Connolly; S J Schnitt
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

10.  Assessment of lesions coexisting with various grades of ductal intraepithelial neoplasia of the breast.

Authors:  Gary L Bratthauer; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2004-02-19       Impact factor: 4.064

View more
  1 in total

Review 1.  Blunt duct adenosis: a separate entity from columnar cell lesions?

Authors:  Mirthe de Boer; Paul J van Diest
Journal:  J Clin Pathol       Date:  2021-04-15       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.